The round brings up Nested’s total financing to date to $125M.

Nested Therapeutics, which is building a next-generation precision medicine platform for hard-to-treat cancers, announced its emergence from stealth with a $90 million Series A round led by Goldman Sachs Asset Management with participation from Foresite Capital, Cowen Healthcare Investments, Section 32, and Avidity Partners. Nested was founded by Versant Ventures. (CISION PR Newswire)

“Our drug discovery platform enables us to find new, overlooked areas of opportunity in the form of high confidence targets with unconventional pockets, while also generating the insights necessary to design therapeutics with novel mechanisms for a perfect fit,” said Darrin Miles, Chief Executive Officer of Nested Therapeutics. “Patients deserve more and better options, and our approach holds the promise to make first- and best-in-class precision oncology treatments available to a larger addressable population.”

The company will use the funding to advance its drug pipeline, additional hiring, and further develop its platform for cancer targets.

“Nested Therapeutics is poised to dramatically increase the number of targets that can be reached through precision medicine, giving more patients an opportunity to be treated with better, more targeted therapies,” said Josh Richardson, M.D., Managing Director at Goldman Sachs Asset Management.

Klaus Hoeflich, Ph.D., Co-Founder and Chief Scientific Officer at Nested said: “Our platform uses insights from an array of fields, including genomics, structural biology, computational biophysics, and artificial intelligence. This opens doors to design novel small molecules for previously known targets with well-understood biology and to target what has been previously undruggable.”

Related Story: BrightEdge, The Venture Arm Of American Cancer Society, Ties Up With VC Third Rock Ventures

Photo by National Cancer Institute on Unsplash